Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Mobia Medical, Inc. on July 30, 2026. The filing reports a corporate governance event: the election of a new director to the Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and does not contain financial performance data.

Material Changes

  • Board Expansion: The Board of Directors increased its size from seven to eight members.
  • New Appointment: Myriam J. Curet, M.D., was appointed as a new Class II director, effective July 30, 2026.
  • Term Details: Dr. Curet's term expires at the 2028 annual meeting of stockholders or until a successor is elected.
  • Independence: The Board determined Dr. Curet qualifies as an independent director under SEC rules and Nasdaq listing standards.

Guidance, Outlook, and Management Commentary

Management Commentary: The filing highlights Dr. Curet's extensive background in medical technology and surgery, including her recent role as Executive Vice President and Chief Medical Officer at Intuitive Surgical, Inc. (retired March 2026). She also serves on the boards of Inspire Medical Systems, Inc. and Stereotaxis, Inc.

Compensation and Arrangements: Dr. Curet will receive compensation as a non-employee director in accordance with the company's standard program. Mobia expects to enter into a standard indemnification agreement. There are no undisclosed arrangements or transactions requiring reporting under Item 404(a) of Regulation S-K.

Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in this filing.

Key Facts for Investor Verification

  • Verify the updated Board composition and the specific term expiration date for the new Class II director.
  • Confirm Dr. Curet's independence status and potential committee assignments in future filings.
  • Review the company's non-employee director compensation program to understand the financial impact of this appointment.
  • Note that this filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.